Envoy Medical, the hearing health company pioneering fully implanted cochlear solutions, announced a major expansion of its intellectual property portfolio with the issuance of three new patents—one in the U.S. and two in Hong Kong. The move strengthens Envoy’s competitive position in the fast-evolving cochlear implant industry.

 

“We believe the future of the cochlear implant industry is fully implanted devices and that our approach is novel when compared to other designs,” said Brent Lucas, Chief Executive Officer of Envoy Medical. “As the industry realizes the wisdom and flexibility of our approach, we will have a strong patent portfolio to help protect our leadership position as a first mover with substantial differentiation.”

 

The new patents cover critical advancements in cochlear implant technology, including improved signal processing, flexible integration with external auditory devices, and advanced electrode impedance diagnostics.

 

Envoy’s management emphasized that as the company advances toward potential Premarket Approval (PMA) submission and commercialization, a robust IP portfolio will be a key strategic and competitive asset.